Abstract Misuse of recombinant human erythropoietin (rhEPO) is a major concern in competitive sports, and the implementation of tests allowing for higher detection rates than what current tests are capable of is required. In this study, a novel lateral flow EPO isoform test kit, EPO WGA MAIIA, is evaluated on the basis of plasma and urine samples obtained from eight healthy males in connection with a 28-day rhEPO injection period. rhEPO was injected every other day during the first 14 days of the study, and the method proved to be 100 % effective in detecting rhEPO in the concomitantly obtained samples. Seven days after the last injection, three positive (>99.99 % confidence limit (CL)) subjects were found. When using 99 % CL as the cut-off limit, six of the eight subjects (75 %) were found to be suspected of doping. Samples obtained 14 and 21 days after the last injection showed no detectable trace of rhEPO. A previous study using indirect methods to determine EPO doping on the same samples indicated only that two of the subjects had suspicious values 7-21 days after the last injection. We propose implementing the easy to-use EPO WGA MAIIA test as an initial screening procedure in antidoping work to (1) increase the detection rate of potential rhEPO doping athletes and (2) allow for a 10-to 20-fold higher analytical rate than what is possible today.
Introduction
Recombinant proteins and peptide hormones, such as recombinant human erythropoietin (rhEPO) seem to be widely abused in sports to enhance performance [1] . Unfortunately, the detection of doping using recombinant proteins is difficult [2] since they only possess minor structural differences as compared with their endogenous forms. Other challenges include the fact that only a small concentration of, for example, injected rhEPO is required in order to increase exercise performance [3] , and that the clearance rate from the body is very high [4] . Endogenous and recombinant EPOs are glycoproteins that can be distinguished by their posttranslational glycosylation pattern, which is specific for the synthesising cell. The basic approach to analytically distinguish between different EPOs is to combine electrophoretic or chromatographic separations of EPO isoforms with sensitive anti-EPO antibody-based detection methods. Capillary isoelectric focusing and zone electrophoresis of EPO isoforms are powerful separation methods for which the detection methods have been enhanced during the past years [5, 6] . These methods are very useful for pharmaceutical analysis but have not yet reached the sensitivity required for measurement of endogenous samples. Endogenous and recombinant EPO glycosylation can be distinguished by charge [7, 8] , isoelectric point [9] , molecular mass [10, 11] or by interaction with specific lectins [12, 13] , and these methods are described in a recent summary [14] . The methods differ in how well they distinguish certain types of glycosylation (the EPO isoform resolution) and by the minimum required amount of EPO for the analysis (the EPO detection sensitivity). The methods often require an additional purification and/or concentration step before urine and plasma can be analysed [15, 16] . The isoform methods rely on a large number of samples from a reference population having been tested in order to select the most suitable cut-off limits for achieving the highest possible specificity and sensitivity for detecting a potential doping misuse with rhEPO.
With the recently developed EPO WGA MAIIA test kit [13, 17, 18] , quantitative values for EPO isoforms are obtained by using the percentage of migrated isoforms (PMI) as unit. Quantitative methods allow estimation of confidence limits (CL) to be calculated from the results for the reference population, as well as quality control within and between runs and laboratories.
The detection of potential rhEPO doping by athletes is hence very challenging [19] [20] [21] [22] [23] [24] , and with the present study, we hope to increase the efficacy hereof.
The newly developed EPO WGA MAIIA method is suggested to be much more sensitive than the IEF method currently applied by the World Anti-doping Agency to fight EPO doping. In samples collected from a major sport event, the method determined 6 % to be positive whereas the IEF method did not flag a single sample to be indicative of EPO doping [13] .
This study evaluates the efficiency to detect potential rhEPO abuse in plasma and urine samples obtained from volunteers injected with rhEPO. Based on the hypothesised higher sensitivity, we expected that the MAIIA method would prove superior as compared with other methods in their ability to determine EPO doping.
Methods

Samples collected in the rhEPO injection study
Urine and blood plasma samples were obtained from a recently performed study [19] . In short, all samples were obtained from eight healthy male volunteers (23±3 years) before, during and after ten s.c. injections of 5,000 IU (65 IU±5/kg bodyweight) of NeoRecormon®. This pharmaceutical glycoprotein belongs to the group of epoetin beta. The samples were collected before (−14 and −10), and 2 days after, injection, during days 2-16, and finally 7, 14 and 21 days after injection at days 35, 42 and 49, respectively. The injection and collection regimen is illustrated in Fig. 1 .
Reference population of urine and plasma samples Urine samples from 25 healthy volunteer donors (men and women between 20 and 60 years of age) were collected after approval by the local ethical committee (No. 2005:307) and combined with eight pre-samples from the injection series to establish the reference values for EPO WGA MAIIA. The 16 pre-samples of plasma from the injection series and seven additional EDTA plasma samples (leftovers from a routine medical health check-up) were used as reference plasma samples. All specimens were stored in aliquots at −20°C until analysed.
Affinity purification of EPO prior to MAIIA test EPO from 0.4 mL of plasma and 5 mL of urine samples was purified according to the instructions from the producer (EPO Purification Kit, MAIIA Diagnostics, Uppsala, Sweden). The EPO affinity purification recovery was 62.5 % for the 85 plasma samples and 39 % for the 67 urine samples. The EPO concentration in urine, plasma and purified sample was determined using a commercially available kit (EPO Quantification Kit, MAIIA Diagnostics). The affinity purification kit has been evaluated recently [15, 16] . Following this procedure, it took 20 min to obtain affinity purified and concentrated EPO samples from 5 mL of urine.
The MAIIA isoform analysis A MAIIA kit (EPO WGA MAIIA prototype Kit, MAIIA Diagnostics) was used to analyse affinity-purified EPO from urine or plasma samples in accordance with the instructions from the supplier. The analytical principle, procedure, standardisation and scanner equipment have been described recently [13] . The MAIIA lateral flow strip contains both a wheat germ agglutinin (WGA) lectin zone and downstream from this, an anti-EPO zone. Briefly, after immersing the strip in a well containing the sample, all EPO is bound in the first tenth of the 8-mm-long WGA zone. Then, the strip is moved to a second well for desorption of EPO, from its WGA interaction, by a WGA competing sugar derivate, Nacetylglucosamine (GlcNAc). Two strips were used to obtain total desorption (using high concentration of GlcNAc, 100 mM), and two strips were used for retarded desorption of EPO for each sample (using 10 mM of GlcNAc). Desorption from the WGA binding starts the migration of EPO, and the most rapidly migrating ones can pass the WGA zone and be captured in the subsequent anti-EPO zone on the strip. Desorption was interrupted after 5 min by removing the WGA zone by cutting. EPO bound to the anti-EPO zone was reacted with anti-EPO bound to carbon black nano-string, and the obtained grey to black signal intensity was quantified with an image scanner and compared with the signal obtained for an rhEPO standard. The PMI unit was obtained by calculating (EPO amount released during retarded conditions using 10 mM GlcNAc)/(total amount of EPO released using 100 mM GlcNAc)×100. It took about 30 min to obtain the results from one test run.
Determination of EPO concentration in urine using lateral flow immunoassay
The method, combining desalting and quantification using an EPO Quantification Kit, has been presented elsewhere [25] .
Determination of EPO concentration in plasma using lateral flow immunoassay
An EPO Quantification Kit (MAIIA Diagnostics) was used in accordance with the instructions from the supplier, but some additional steps were required for the plasma measurement. The plasma samples were diluted eight times in a 20-mM phosphate buffer at pH 7.5, supplemented with 6 % BSA, 0.1 M NaCl and 0.02 % NaN 3 . In each well, 25 μL of diluted sample was mixed with 25 μL of 20 mM phosphate buffer at pH 7.5 supplemented with 1 % BSA, 0.1 M NaCl, 0.1 % bovine gamma globulin, 0.02 % monoclonal mouse IgG, 1 % Tween 20 and 0.05 % NaN 3 . 0.02 % monoclonal mouse IgG was added to the working solution of anti-EPO carbon black nano-strings.
Statistics
Values are presented as means±SD. Differences in results for the groups before and after administration of the drug were examined by paired t test (SigmaPlot 12, Systat Software, USA) after normal distribution of control using the ShapiroWilk test. Statistical significance was accepted at P<0.05 (*); P<0.01 (**) and P<0.001 (***).
Each individual result before and after administration of the drug was also compared with the one-tailed CL, calculated from the results for the reference population. Limits selected at 99.99, 99.9, 99.0 and 97.8 % allow that 0.1, 1, 10 or 22 normal samples out of 1,000 samples are outside the limit and regarded as aberrant.
Results
EPO WGA MAIIA results during the boosting, maintenance and wash-out period Eight subjects were each administrated with ten s.c. doses of 5,000 IU epoetin beta (65 IU±5/kg), and the injection regime and results are shown in Fig. 1 . The EPO WGA MAIIA isoform analysis demonstrated a highly significant (P<0.001) change in values between the pre-treatment samples (day −14) and the samples collected 2 days after injection, at days 2-16 for plasma (panel A) as well as urine samples (panel B). The plasma samples collected on day 35, 7 days after the last injection (n=7), showed significantly (P=0.041) decreased values compared with pre-treatment values for the isoform test. The results from the urine samples (n=6) collected the same day were significantly (P=0.005) decreased compared with samples collected on day −14. The results at 14 and 21 days after the last injection could not be distinguished from pretreatment sample results.
Plasma and urine EPO concentration during the test period
The plasma and urine EPO concentration was determined by the EPO lateral flow immunoassay and is shown in Fig. 1 . For the 16 plasma samples collected before any injection, at days −14 and −10, the EPO concentration was 99.9 ± 43.2 ng/L, while the concentration increased significantly (P<0.001) to 300±90.5 ng/L for the 47 samples collected on days 2 to 16, 2 days after the previous injection. The individual mean plasma EPO concentrations were in the range of 240-396 ng/L for the eight subjects during days 2-16. The urine EPO concentration was 20.4±13.1 ng/L for the eight samples collected before injection and 72.9±71 ng/ L at days 2 to 16, collected 2 days after the previous injection. As expected, a considerable variability in the urine EPO concentration was present.
At day 35, the total concentration of EPO had returned to normal values, while the EPO WGA MAIIA values still show a presence of epoetin beta.
Analysis of samples to obtain the reference range
The analysis of the reference samples revealed 73.0±6.5 PMI for the 33 urine specimens, with a range from 61. 8 The PMI values can be compared with affinity-purified recombinant epoetin beta that gave PMIs of 26.6±2.1 and 24.9±2.0 when used as controls for the presented urine (n=13) and plasma (n=8) test runs, respectively.
Imprecision for the EPO WGA MAIIA
In each test run, three control preparations were included, containing (1) affinity-purified endogenous EPO in urine from one healthy subject, (2) affinity-purified epoetin beta applied to buffer and (3) a known mixture of 60 % endogenous and 40 % of epoetin beta. The inter-assay CV was 8.2 % when tested on 21 different test occasions for the three controls between 25 and 77 PMI.
The immunoassay measurement for retarded and total desorption mode demonstrated a median coefficient of variation (CV) of 4.7 % betwexcen the duplicates when 603 samples from the injection series, the reference samples and several controls were measured.
Comparing plasma and urine sample analyses
In order to reveal if the detectability of epoetin beta is different in plasma and urine samples, the results for plasma and urine samples collected on days −14, 16 and 35 are shown in Fig. 2 . All samples collected on day 16, 2 days after the last injection, were clearly outside the 99.99 % CL. The samples collected on day 35, 7 days after the last injection, were the most interesting ones for sensitivity comparison, as the method seemed close to its doping detecting limit. For the five subjects having both urine and plasma results, one plasma sample and four urine samples were found to be outside the 99.0 % CL. This indicates that the analysis of urine samples gives a slightly wider detection window than plasma samples.
The MAIIA results at day 35, 7 days after the last injection The individual EPO WGA MAIIA values, haemoglobin and haematocrit values at day 35 are given in Table 1 . In total, seven plasma samples from day 35 were analysed, and one of these was outside 99.99 % CL, but unfortunately, the corresponding urine sample for that specific sample was not available. There were six urine samples available for analysis from that particular day and two of them where outside 99.99 % CL.
By combining the MAIIA results for plasma and urine collected on day 35, results for all eight subjects were obtained. Three of the eight subjects (38 %) showed results outside the 99.99 % CL while 75 % (six of eight) was outside the 99.0 % CL. The haemoglobin and haematocrit values were exceeding the limit [26] of 170 g/L and 50 %, respectively, for only one of the subjects, who would have been excluded from starting competition. This subject also had a haematocrit value above the limit (50.5 %) at day 42, 14 days after the last injection. Subject 16 had a haematocrit The samples collected at day 16, 2 days after the last injection, are all well outside the 99.99 % CL for both urine and plasma. The interesting day for comparing test sensitivity is day 35, 7 days after the last injection. For the five subjects having both urine and plasma samples, it was found that one plasma samples and four urine samples were outside the 99 % CL and regarded as doping suspected samples. Both plasma and urine samples can be used for analysis, but the results indicate that traceable amounts of epoetin beta remain in urine, but have left blood, at 7 days after the last injection value of 50.4 % at day 49, 21 days after the last injection, which would have excluded him. The limits were not exceeded for any of the subjects on any other sampling days.
Discussion
The present study evaluated the detection efficiency of a novel lateral flow isoform test, EPO WGA MAIIA, intended for EPO anti-doping control, on samples collected before, during and after s.c. injections with epoetin beta in eight healthy males. The main finding is that the EPO WGA MAIIA method can determine rhEPO injections during a 14-day period with a high injection rate, as well as up to 7 days after a period with less-frequent injections. Both urine and plasma samples can be used for doping analysis, although the results indicate that urine is a better specimen than plasma for epoetin beta.
Other tests performed on the samples collected from the present study
The urine samples collected from the same injection series were analysed by means of IEF as shown in a previous publication [19] and demonstrated two out of seven (29 %) tested samples as positive on day 35. The use of indirect methods [27] to identify EPO doping for the samples from the study presented herein has also been presented elsewhere [28] . During the entire sample collection period of 49 days, very few of the eight subjects exceeded the cut-off limit (99.9 % CL) for OFF z score (two subjects), percentage of reticulocytes (two subjects), Hb z score (one subject) and OFF hr score (no subjects). The limit for percentage of reticulocytes was exceeded once for two subjects, and only during the injection period where all eight subjects were found to be positive with EPO WGA MAIIA. OFF z score showed one subject outside the 99.9 % CL on days 35 and 42 while another subject was outside the limit at day 49.
Aerobic exercise capacity was significantly increased on days 35, 42 and 49 [19] , with the peak value determined on day 42. During these days, 7-21 days after the last injection, three subjects were positive (99.99 %) and another three subjects were suspicious (99.0 %) for doping using EPO WGA MAIIA, while only two subjects exceeded the 99.9 % limit with OFF z score . The EPO WGA MAIIA test, which identified rhEPO both during and up to 7 days after injection, and OFF z score , which in this study indicated misuse 7 to 21 days after the last injection, seems preferable to use in combination.
Detection of different types of rhEPO
In this study, the ability for isoform methods to detect injections specifically using epoetin beta was studied. An optimal EPO doping control method should be able to distinguish all different recombinant EPOs and all available EPO-like molecules [24, 29, 30] from at least two to three different endogenous EPO populations. The EPO WGA MAIIA method has previously proven to be successful in the detection of several isoforms of EPO [13] , such as epoetin alpha, omega, delta, darbepoetin alpha and CERA. The method has also successfully identified the injection of As all samples were not available for testing, both the plasma and urine results are used to settle the suspicions for doping. Three of the subjects will be positive for doping (10, 11 and 13) being outside the 99.99 % CL. Three of the subjects might be suspected for doping (9, 12 and 15) being outside the 99 % CL while only two subjects are negative (25 %). The haemoglobin and haematocrit values exceed not the limits for competition, with the exception of one subject (13) N normal value, NA not analysed epoetin-and darbepoetin alpha in horses [17] . EPO WGA MAIIA has also been used for detecting intravenous administration of epoetin beta 72 h after the last injection [18] . Both plasma and urine samples can be used for analyses, but the results indicate that detectable traces of epoetin beta remains longer in urine than in plasma. Other epoetins and epoetin variants may differ in excretion pattern and should be tested with injection series. The macromolecular EPO variant CERA has a reduced urine excretion [31] and most probably plasma samples would show the best sensitivity. Presently, for the IEF-based doping analysis, urine samples are the preferred type of specimen, and the introduction of blood collection will require changes in practical details connected with the sample collection.
The minimal amount of rhEPO required for detection
The EPO detection sensitivity of the isoform method seems sufficient to distinguish isoforms of rhEPO in urine samples containing as little as 0.1 to 1 ng/L (3 to 30 fmol) of EPO. This is crucial since very low EPO concentrations were found in several urine samples collected during a major competition [13] . The MAIIA method was able to determine that these samples had aberrant EPO forms while the EPO amount was too low for IEF analyses. In the present study, all samples were analysed using only 5 mL of urine for affinity purification as compared with the 20 mL required for IEF doping method. It was calculated that even 2.5 mL of urine had been sufficient for analysis of all the samples in the series.
The increased sensitivity may be due to better detection sensitivity as well as the high EPO recovery of the affinity purification regime required prior to the isoform test procedure.
Conclusions
The sensitive and easy-to-use MAIIA method with a process time of just 1 h, and with potential for large-scale testing, seems to be a very good candidate for a screening tool against EPO doping. This test demonstrated a higher detection rate than the other direct and indirect EPO doping tests that were tested on the samples from the presented epoetin beta injection series.
The on-going EPO doping in sport has to be stopped [1] . Today's acknowledged methods to determine EPO doping are unfortunately not as efficient as could be wished for. Furthermore, the analytical procedures are not easy to perform and are very expensive. In the present study, it is proposed that the inclusion of an affordable and sensitive screening test against rhEPO doping will lead to higher detection rates than what is seen today. Moreover, the use of quantitative results for isoform tests could allow the implementation of different degrees of suspiciousness. Exceeding a certain limit is suggested to lead to an intense out-of-competition sampling program.
